TY - JOUR T1 - Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent JF - The Journal of Rheumatology JO - J Rheumatol SP - 1216 LP - 1216 DO - 10.3899/jrheum.100830 VL - 38 IS - 6 AU - CARRIE YE AU - DALTON SHOLTER AU - LIAM MARTIN AU - STEPHANIE KEELING Y1 - 2011/06/01 UR - http://www.jrheum.org/content/38/6/1216.abstract N2 - To the Editor:We read with interest the recent letter1 and editorial2 discussing anti-tumor necrosis factor (anti-TNF)-induced lupus requiring cessation of therapy for disease resolution. A lack of published experience of successful TNF inhibitor switching (8 total cases in the literature) causes concern for rheumatologists faced with this clinical scenario. We describe 2 more patients who successfully switched to different TNF inhibitor after developing anti-TNF-induced lupus. A 43-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) achieved remission when treated with adalimumab 50 mg biweekly 8 years ago. Adalimumab was increased to 50 mg weekly when she developed an arthritis flare. Her arthritis worsened and she developed severe pleuritis but no other lupus features. Laboratory investigations revealed anti-dsDNA antibodies that were not present in her preadalimumab antibody profile and persistence of anti-SSA antibodies that were present prior to adalimumab. A diagnosis of adalimumab-induced lupus was made and adalimumab was discontinued. Her symptoms resolved while taking prednisone … Address correspondence to Dr. Keeling; E-mail: stephanie.keeling{at}ualberta.ca ER -